AstraZeneca Remuneration April Report 2016

Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful) Manifest has assessed the Company’s disclosures against the recommendations of the UK Corporate Governance Code, institutional investor guidelines and the disclosure requirements set out in both the Companies Acts and the UKLA Listing Rules. The following items have been identified which may be of interest to shareholders: Remuneration policy establishes a strong alignment between executive remuneration and Company strategy. Total remuneration awarded/received could be deemed excessive considering the performance of the Company. Incentive remuneration opportunity could be deemed excessive. There is incomplete disclosure of annual bonus targets for 2015 and 2016 due to a perceived commercial sensitivity. Targets for 2014 have also yet to be disclosed. Discretion exercised in determination of annual

...

Not a member? Join today

Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:

Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities

Join now

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.